Treatment of Fabry disease: Outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg

被引：0
|
作者：
Vedder, A. C.
Linthorst, G. E.
Houge, G.
Groener, J. E. M.
Ormel, E. E.
Bouma, B. J.
Aerts, J. M. F. G.
Hirth, A.
Hollak, C. E. M.
机构：
[1] AMC, Dept Intern Med Endocr Metab, Amsterdam, Netherlands
[2] Haukeland Hosp, N-5021 Bergen, Norway
[3] AMC, Dept Biochem Med, Amsterdam, Netherlands
[4] AMC, Dept Cardiol, Amsterdam, Netherlands
[5] Haukeland Hosp, Dept Heart Dis, N-5021 Bergen, Norway
来源：
JOURNAL OF INHERITED METABOLIC DISEASE | 2007年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：118 / 118
页数：1
相关论文
共 50 条
  • [31] Clinical outcomes in elderly patients receiving agalsidase alfa treatment in the Fabry Outcome Survey
    Nowak, Albina
    Botha, Jaco
    Anagnostopoulou, Christina
    Hughes, Derralynn A.
    MOLECULAR GENETICS AND METABOLISM, 2024, 143 (1-2)
  • [32] Four-Year Prospective Clinical Trial of Agalsidase Alfa in Children with Fabry Disease
    Schiffmann, Raphael
    Martin, Rick A.
    Reimschisel, Tyler
    Johnson, Karen
    Castaneda, Victoria
    Lien, Y. Howard
    Pastores, Gregory M.
    Kampmann, Christoph
    Ries, Markus
    Clarke, Joe T. R.
    JOURNAL OF PEDIATRICS, 2010, 156 (05): : 832 - U196
  • [33] Clinical development of agalsidase-beta for the treatment of Fabry disease
    Germain, DP
    M S-MEDECINE SCIENCES, 2005, 21 : 57 - 61
  • [34] Agalsidase alfa for the treatment of Fabry disease: new data on clinical efficacy and safety
    Beck, Michael
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2009, 9 (02) : 255 - 261
  • [35] Switch to agalsidase alfa after shortage of agalsidase beta in Fabry disease: a systematic review and meta-analysis of the literature
    Pisani, Antonio
    Bruzzese, Dario
    Sabbatini, Massimo
    Spinelli, Letizia
    Imbriaco, Massimo
    Riccio, Eleonora
    GENETICS IN MEDICINE, 2017, 19 (03) : 275 - 282
  • [36] Positive European experience with agalsidase alfa in Fabry disease: update from FOS - the Fabry Outcome Survey.
    Mehta, A
    Beck, M
    Dehout, F
    de Lorenzo, AG
    Hauge, G
    Jaeger, P
    Kampmann, C
    Linhart, A
    Ricci, R
    Sunder-Plassman, G
    Widmer, U
    AMERICAN JOURNAL OF HUMAN GENETICS, 2003, 73 (05) : 453 - 453
  • [37] Evaluation of glycosphingolipid clearance in patients with Fabry disease treated with agalsidase alfa who switched to agalsidase beta (the INFORM study)
    Barranger, John A.
    Gambello, Michael J.
    Goker-Alpan, Ozlem
    Maegawa, Gustavo H. B.
    Nedd, Khan J.
    Gruskin, Daniel J.
    Blankstein, Larry
    Weinreb, Neal J.
    MOLECULAR GENETICS AND METABOLISM, 2014, 111 (02) : S24 - S24
  • [38] Agalsidase-beta therapy for advanced Fabry disease - A randomized trial
    Banikazemi, Maryam
    Bultas, Jan
    Waldek, Stephen
    Wilcox, William R.
    Whitley, Chester B.
    McDonald, Marie
    Finkel, Richard
    Packman, Seymour
    Bichet, Daniel G.
    Warnock, David G.
    Desnick, Robert J.
    ANNALS OF INTERNAL MEDICINE, 2007, 146 (02) : 77 - 86
  • [39] An open-label, switchover trial to assess the safety and efficacy of agalsidase beta in patients with Fabry disease treated with agalsidase alfa enzyme replacement therapy
    Richards, Sarah
    Laney, Dawn
    Pervaiz, Muhammad A.
    Shankar, Suma
    MOLECULAR GENETICS AND METABOLISM, 2014, 111 (02) : S90 - S90
  • [40] Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis
    Beck, Michael
    Hughes, Derralynn
    Kampmann, Christoph
    Larroque, Sylvain
    Mehta, Atul
    Pintos-Morell, Guillem
    Ramaswami, Uma
    West, Michael
    Wijatyk, Anna
    Giugliani, Roberto
    MOLECULAR GENETICS AND METABOLISM, 2015, 114 (02) : S19 - S20
12345